Objective: The objective of this study was to determine the association of copy number variants (CNV) with perinatal outcomes among fetuses with sonographic abnormalities.
| INTRODUCTION
Chromosomal microarray (CMA) has become the first-tier genetic test for the evaluation of fetuses and children with congenital anomalies and neurodevelopmental disorders.
1,2 CMA provides genetic information at a higher resolution than conventional karyotyping by detecting copy number variants (CNV)-submicroscopic chromosomal deletions or duplications-as small as 50 to 100 kilobases. CNV are interpreted as benign, pathogenic, or variants of uncertain significance (VUS) depending on the specific location, genes affected, and the level of existing evidence linking the variant with a phenotype. The introduction of CMA into clinical practice over the past decade has significantly increased the diagnostic yield of genetic testing in several scenarios, including cases of congenital anomalies, stillbirth, cerebral palsy, intellectual disability, developmental delay, and autism spectrum disorders. [3] [4] [5] [6] [7] [8] CMA may also be of diagnostic utility in the setting of nonimmune hydrops fetalis (NIHF). 5, 9 CMA has been shown to detect clinically relevant deletions or duplications in 6% of euploid fetuses with one or more structural anomalies, and is routinely recommended when anomalies are detected by prenatal ultrasound. 1, 2, 6 While an abnormal fetal karyotype in this setting is often associated with an increased risk of perinatal demise, it is uncertain if CNV have the same implications. 10, 11 Understanding the prognostic impact of these genetic abnormalities may provide clarity for expectant families, shape expectations, and serve as a basis for counseling regarding the risk of recurrence in future pregnancies. The likelihood of survival is particularly important, and may guide critical clinical management decisions, such as choosing comfort care, in utero therapy, or aggressive resuscitation at birth.
Whether CMA is a useful predictor of outcomes, including survival, in fetuses with anomalies is unknown.
The objective of this study was to evaluate the association of CMA with perinatal death among anomalous fetuses, as well as with additional outcomes, including mode of delivery, preterm birth, small for gestational age (SGA) birth weight, prolonged hospitalization, and death prior to discharge from the hospital. We hypothesized that fetuses with abnormal CMA results would have a greater risk of perinatal death and other adverse perinatal outcomes.
| METHODS
This was a retrospective cohort study of fetuses with structural anomalies or NIHF identified on prenatal ultrasound, who underwent genetic evaluation with CMA. Patients referred to the University of California, San Francisco (UCSF) Fetal Treatment Center (FTC), with estimated due dates between January 1, 2011, and September 1, 2016, were identified through the FTC database and evaluated for inclusion. Inclusion criteria were singleton or twin pregnancies with at least 1 fetal structural anomaly or NIHF for which a prenatal or postnatal CMA was performed.
Monochorionic-and dichorionic-diamniotic twin pregnancies were included, with outcomes analyzed per pregnancy (all of these cases involved only 1 anomalous fetus). Pregnancies for which fetal anomalies
were not confirmed by ultrasound at our institution, information regarding pregnancy outcome or perinatal survival was unobtainable, and cases in which hydrops was attributable to isoimmunization or twin-twin transfusion syndrome (TTTS) were excluded. Adjusted odds ratios (aOR) with 95% confidence intervals (CIs) were reported. All tests were 2-tailed and a P value of <.05 was considered significant. STATA version 13.1 was used to perform statistical analyses.
| RESULTS
There were 304 fetuses identified with CMA results, of which 24 were excluded for the following reasons: a change in the referral diagnosis
What's already known about this topic?
• Chromosomal microarray (CMA) testing increases the diagnostic yield when fetal anomalies are found on prenatal ultrasound. Information about the impact of copy number variants (CNV) on perinatal outcomes is limited.
What does this study add?
• In our study, CNV were not associated with increased odds of perinatal death among fetuses with structural anomalies or nonimmune hydrops.
(i.e. normal ultrasound) upon evaluation at our center (n = 8), referral without evaluation (n = 6), TTTS without anomalies in either fetus (n = 2), monoamniotic twin or triplet gestation (n = 4), or perinatal outcome unknown (n = 4). Outcome data were available for 280 pregnancies ( Figure 1 ). Sixty (21.4%) had abnormal CMA results, including 21 (7.5%) pathogenic and 39 (13.9%) VUS.
Baseline clinical characteristics of the study cohort are shown in Table 1 . Normal and abnormal CMA groups were similar with respect to maternal age, parity, fetal sex, presence of multiple anomalies, and types of anomalies. Most results were based on prenatal diagnostic testing (72.5%). All patients with postnatal CMA had testing done prior to hospital discharge. A higher proportion of patients with abnormal CMA had postnatal testing compared to those with normal CMA, 55% vs 20% (P < .001), respectively. Most fetuses that were tested prenatally had normal CMA results (176/203, 86.7%).
Overall, 68 (24.3%) women elected termination of pregnancy.
Outcomes for the remaining 212 ongoing pregnancies are shown in Abbreviations: CMA, chromosomal microarray; GI, gastrointestinal.
Data are mean ± standard deviation or n (%).
a Including thoracentesis ± shunt, open neural tube defect repair, vesicocentesis ± shunt, percutaneous umbilical blood sampling ± intrauterine transfusion, fetoscopic balloon tracheal occlusion, aortic valvuloplasty, laser ablation for twin-twin transfusion syndrome, and radiofrequency ablation for severe, selective growth restriction of anomalous donor twin.
hospitalization, and death prior to discharge from the hospital (Table 2) .
Overall, cesarean delivery occurred in 50% of pregnancies, and approximately 40% of infants who survived the neonatal period required prolonged hospitalization. When we excluded VUS and examined only pathogenic CNV vs normal CMA cases, our results were similar; the presence of a pathogenic CNV was not associated with perinatal death, and the specific anomalies found to be independent predictors of perinatal mortality risk when VUS were included remained associated. To evaluate the effect of including twin pregnancies, a stratified analysis of singleton pregnancies was performed, which revealed no differences in results when twins were excluded.
Outcomes for abnormal CMA cases were further examined by CNV classification (Table 3) . Among fetuses with an abnormal CMA result, a pathogenic variant was identified in 21 subjects (35.0%), and a VUS was found in 39 (65.0%). There were no significant differences in primary or secondary outcomes between subjects with pathogenic variants vs VUS. Table 4 details the specific CNVs and types of anomalies for cases of perinatal death and death prior to hospital discharge, including Abbreviations: CMA, chromosomal microarray; VUS, variant of uncertain significance.
Data are n (%) unless otherwise specified.
Number of missing values: small for gestational age, 4 (1 pathogenic, 3 VUS); prolonged hospitalization, 6 (4 pathogenic, 2 VUS); death prior to discharge, 6 (4 pathogenic, 2 VUS).
a Prolonged hospitalization defined as length of stay >28 days if delivered at ≥36 weeks of gestation or > the number of days needed to correct birth gestational age to 40 weeks if delivered at <36 weeks of gestation among those who survived the neonatal period.
the most detailed CNV information available. In some cases where women were referred from outside institutions, the full CMA report including genomic coordinates was not available. Additional CNV information for the remaining abnormal cases is provided in Appendix S1. Table 5 ). All but 2 of these subjects had a normal CMA 
| DISCUSSION
We investigated the prognostic value of CMA in fetuses with sonographic abnormalities in a diverse cohort of pregnancies across a >5-year time span. A pathogenic variant or VUS was detected in over 20% of cases, with the majority being a VUS. Among fetuses with and without abnormal CMA results, we found no difference in perinatal death, or the secondary outcomes of mode of delivery, preterm birth, SGA birth weight, prolonged hospitalization, and death prior to discharge from the hospital. Factors associated with perinatal death included hydrops and specific anomalies, such as CDH and genitourinary anomaly.
The reported prevalence of abnormal CNV in euploid fetuses with anomalies is 6% to 10%, although the association of CNV with specific categories of anomalies or multiple anomalies is higher. 5, 6, 13, 14 In a recent study of infants with congenital heart disease, for example, clinically significant CNV or VUS were detected in 29% of subjects who underwent postnatal CMA testing. 15 We anticipated a high proportion of abnormal CMA results based on our high-risk study population, which was enriched for major and complex anomalies. Therefore, the 2-to 3-fold higher frequency of CMA abnormalities and relatively poor perinatal outcomes likely reflect the nature of the cohort and the types of anomalies referred to centers specializing in fetal diagnosis and therapy, as well as the selection of more severe cases for testing.
Most of the abnormal CNV detected in our cohort were VUS, which may become reclassified over time. For instance, Wapner et al reported that 38 of 94 cases (40.4%) of VUS were reclassified by the time their 5-year study was complete; 30 were reclassified as clearly pathogenic, and 8 as likely benign. 6 We reviewed older CMA results (obtained prior to 2014) in our cohort; however, none of the 23 cases had sufficient new data to be reclassified. The frequent identification of VUS is a common challenge in genetics, 16 especially when identified prenatally, and patients should be informed of the potential for this finding and the limitations of their interpretation when prenatal diagnosis is undertaken.
Strengths of this study include the measurement and follow-up of clinically meaningful outcomes, and evaluation of a high-risk cohort.
One of the challenges of studying a referral population is obtaining outcomes for patients who deliver at various hospitals. Very few of the eligible cases identified through our institutional database were lost to follow-up, despite only 70% delivering at our institution.
During the study period, 1825 patients were referred to the FTC for suspected fetal anomalies. Among 1477 continuing pregnancies, there were 199 (13.5%) perinatal deaths overall; this outcome occurred in 21.2% of patients with CMA testing vs 12.2% without testing (P < .001). Among cases of perinatal death, the rate of any CMA testing was 22.6% (17.6% for prenatal CMA). The higher proportion of perinatal deaths in the CMA study cohort might be explained in part by differences in who was tested, i.e. an inclination toward CMA testing in cases Lastly, the limitations of retrospective chart review apply to this study, such as the potential for missing data due to differential loss to followup, which is particularly relevant to referral populations. However, because the FTC database is actively managed with data added regularly on a prospective basis, we expect that these limitations were minimized.
Ten percent of the cohort had a prenatal therapeutic procedure, Finally, a relatively high proportion of women elected termination of pregnancy. These were not included in the outcomes analysis as we were unable to study the primary outcome for these pregnancies. Among women with prenatal testing results who chose termination, over 80%
had a normal CMA, suggesting that most of the decisions were driven by the severity of ultrasound findings rather than CMA results. Indeed, 25% of women electing termination had CMA testing postprocedure.
In conclusion, CNV were detected in over 20% of our cohort of fetuses with major structural anomalies or NIHF, and there was a high rate of perinatal death among those with both normal and abnormal CMA results. However, we did not find an association between abnormal CMA and perinatal death, mode of delivery, preterm birth, SGA birth weight, prolonged hospitalization, or death prior to hospital discharge. Our findings suggest that although fetuses with ultrasound abnormalities are at increased risk of having a CNV detected on CMA, those with abnormal CMA results are not at greater risk of perinatal death overall compared to those with normal results. This may change over time as we gather more genetics data that will improve our ability to classify variants as benign or pathogenic, and future studies should reassess these relationships in separate populations. This study further highlights the need for comprehensive genetic counseling in each of these cases, particularly when a VUS is detected.
